Antoni Ribas

University of California, Los Angeles — United States

Medicine · Health Sciences

157h-index160.7kcitations1.7kworks3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(715), Cancer Immunotherapy and Biomarkers(671), Melanoma and MAPK Pathways(540), Immunotherapy and Immune Responses(466), Cutaneous Melanoma Detection and Management(177)

Publications1.7k total

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Science·2026
The Next Chapter of <i>Cancer Immunology Research</i>
Cancer Immunology Research·2026
Figure S5 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Figure S6 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Table S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Figure S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Table S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Figure S4 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Figure S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Figure S3 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
2025Open Access
Supplementary Tables S1-S11 from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
2025Open Access
Supplementary Figures S1-S6, Figure Legends, and Table Legends from Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
2025Open Access
David Baltimore (1938–2025)
Nature Biotechnology·2025
Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology
Journal of Thoracic Oncology·2025· 1 citedOpen Access
High-throughput identification and analysis of antigen-specific CD4+ T cells 4384
The Journal of Immunology·2025Open Access
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
Nature·2025Open Access
Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025Open Access
Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025Open Access
Data from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025Open Access
Supplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
2025Open Access
page 1 of 86Next →

Frequent Co-authors

Caroline Robert(16), Jeffrey A. Sosman(13), Keith T. Flaherty(13), Bartosz Chmielowski(11), Georgina V. Long(11), Grant A. McArthur(10), Omid Hamid(10), James Larkin(9), Jedd D. Wolchok(9), Adil Daud(9), Roger S. Lo(9), Claus Garbe(8), F. Stephen Hodi(8), Richard Kefford(8), Paul B. Chapman(7), Axel Hauschild(7), John B.A.G. Haanen(7), Paul Lorigan(7), Dirk Schadendorf(7), Jacob Schachter(7)